Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies

E.R. Volkmann, MD, Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA.
S. Assassi, MD, Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, USA.
C.P. Denton, MD, University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK.
R. Simonovska, MSc, mainanalytics GmbH, Sulzbach (Taunus), Germany.
S. Sambevski, MD, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
M. Alves, MD, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
E.J. Bernstein, MD, MSc, Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.

Contributions: E.R. Volkmann: Conceptualization; Visualization; Writing – original draft. S. Assassi: Investigation; Writing – review & editing. C.P. Denton: Investigation; Writing – review & editing. R. Simonovska: Formal analysis; Methodology; Visualization; Writing – review & editing. S. Sambevski: Visualization; Writing – review & editing. M. Alves: Methodology; Supervision; Visualization; Writing – review & editing. E.J. Bernstein: Conceptualization; Visualization; Writing – review & editing. Funding: The SENSCIS trial was supported by Boehringer Ingelheim.
Competing interests: Elizabeth R Volkmann reports research support from Boehringer Ingelheim, GlaxoSmithKline, Horizon, Kadmon, National Heart, Lung and Blood Institute, Prometheus; consulting fees from AbbVie, Boehringer Ingelheim, GlaxoSmithKline; and speaker fees from Boehringer Ingelheim. Shervin Assassi reports research support from Boehringer Ingelheim, Janssen, aTyr and consulting fees from AstraZeneca, aTyr, Abbvie, Merck, Mitsubishi Tanabe, Takeda, Boehringer Ingelheim, CSL Behring, TeneoFour. Christopher P Denton reports research support from Abbvie, Arxx Therapeutics, CSL Behring, GlaxoSmithKline, Horizon, Servier; consulting fees from Abbvie, Acceleron, Arxx Therapeutics, Bayer, Boehringer Ingelheim, Certa, Corbus, CSL Behring, Galapagos, GlaxoSmithKline, Horizon, Inventiva, Janssen, Lilly, Novartis, Roche, Sanofi-Aventis, Zurabio; and speaker fees from Boehringer Ingelheim, Corbus, Janssen. Rozeta Simonovska is an employee of mainanalytics GmbH, Sulzbach (Tanus), Germany, which was contracted by Boehringer Ingelheim to perform analyses presented in this paper. Steven Sambevski and Margarida Alves are employees of Boehringer Ingelheim. Elana J Bernstein reports research support from Boehringer Ingelheim, BMS, aTyr and consulting fees from Boehringer Ingelheim and Cabaletta.
Ethics: The SENSCIS trial was performed in 32 countries and was approved by an independent ethics committee or institutional review board at every site. All patients provided written informed consent before trial entry.

Corresponding author: Elizabeth R Volkmann, David Geffen School of Medicine, University of California, 1000 Veteran Avenue, Ste 32-59, Los Angeles, CA 90095, USA. E-mail: EVolkmann@mednet.ucla.edu